About one in eight U.S. adults say they take a GLP-1 drug, according to a poll by the Kaiser Family Foundation. And that raises a number of questions for investors. As use of drugs such as Ozempic, Wegovy and Zepbound grows, the effects are moving far beyond healthcare and into the way people eat, shop, and spend.
In this episode of The Important Part, Liz Thomas sits down with Caleb Silver, editor-in-chief of Investopedia and Chief Business Editor at People Inc., to examine the rise of the “GLP-1 economy.” Together, they explore how changing consumer behavior could affect food companies, restaurants, apparel, travel, home appliances, telehealth, and the pharmaceutical industry.
Liz and Caleb also discuss where new demand may emerge, which established businesses could face pressure, and what investors should watch as the GLP-1 market continues to develop. Can major brands adapt quickly enough, or will a new group of companies be built around this changing consumer?
This episode is for informational purposes only and should not be considered investment or medical advice.
For more, read Liz’s column every Thursday at On The Money by SoFi, and follow Liz on Twitter @LizThomasStrat.
On The Money: Sign up for SoFi's newsletter for intel, insights, and inspo to help you get your money right.
Investing 101 Center: At SoFi, we believe investing is for everyone — which is why we’ve created a hub with info for beginners and experts alike. Start exploring to get investment education, advice, resources, and more.
Wealth Investing Guide: Information you need to know to make your money work harder for you.
This podcast should be used for informational purposes only and not deemed as a recommendation. Our Automated investing is via SoFi Wealth LLC, and is a registered investment advisor. Our Active investing is via SoFi securities LLC, member FINRA/SIPC. For additional disclosures related to the SoFi Invest® platforms, please visit www. SoFi.com/Legal.
©2026 Social Finance, Inc. All Rights Reserved.